"Another new and exciting development is with our antibody-drug conjugates (ADCs) for solid cancer therapy. Both IMMU-132 (TROP-2-SN-38) and IMMU-130 (labetuzumab-SN-38) have produced partial responses and stable disease in patients who have failed multiple prior therapies, including irinotecan, the parent drug of SN-38. While IMMU-130 is focused on colorectal cancer, IMMU-132 has produced partial responses in very advanced colorectal, triple negative breast and small cell lung cancer patients. Both programs have entered into Phase II clinical development," Ms. Sullivan added."In all, more than 80%, or 20 of the 24 assessable patients, showed evidence of disease control with stable disease or partial responses achieved with IMMU-132 in the Phase I trial just completed. Impressively, this includes 8 patients who had failed prior irinotecan-containing therapies. Because irinotecan is the parent of SN-38, we postulate that the increased amount of SN-38 delivered to the tumors by our ADCs overcomes the tumor's resistance to this class of drugs," commented Dr. William A. Wegener, Senior Vice President of Clinical Research, in his summary of the year's clinical developments focusing on the Company's two most exciting programs, one in pancreatic cancer and the other in solid cancers with our antibody-SN-38 conjugates.
Immunomedics Announces Outcome Of 2013 Annual Meeting Of Stockholders
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.